

=> d his

(FILE 'HOME' ENTERED AT 12:11:14 ON 01 MAY 2007)

FILE 'REGISTRY' ENTERED AT 12:11:45 ON 01 MAY 2007

L1 STRUCTURE UPLOADED

L2 35 S L1 SSS SAM

L3 13964 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 12:25:47 ON 01 MAY 2007

L4 6 S L3 AND DACTYLORHIN B

L5 60 S L3 AND DEMENTIA?

L6 1 S L5 AND MEDICINE?

L7 59 S L5 NOT L6

L8 6 S L7 AND COMPOSITION?

L9 97 S L3 AND BUTANEDIOIC

L10 0 S L9 AND DEMENTI?

L11 0 S L9 AND NEUROLOG?

L12 0 S L9 AND NEVR?

L13 2 S L9 AND NERV?

L14 0 S L9 AND EXTRACT?

L15 0 S L9 AND COELOGLOSS?

L16 7 S L3 AND COELOGLOSS?

L17 134 S L3 AND ALZHEIMER?

L18 14 S L17 AND SUCCIN?

=> d his

(FILE 'HOME' ENTERED AT 12:11:14 ON 01 MAY 2007)

FILE 'REGISTRY' ENTERED AT 12:11:45 ON 01 MAY 2007

L1 STRUCTURE UPLOADED

L2 35 S L1 SSS SAM

L3 13964 S L1 SSS FULL

FILE 'CAPLUS, MEDLINE' ENTERED AT 12:25:47 ON 01 MAY 2007

L4 6 S L3 AND DACTYLORHIN B

L5 60 S L3 AND DEMENTIA?

L6 1 S L5 AND MEDICINE?

L7 59 S L5 NOT L6

L8 6 S L7 AND COMPOSITION?

L9 97 S L3 AND BUTANEDIOIC

L10 0 S L9 AND DEMENTI?

L11 0 S L9 AND NEUROLOG?

L12 0 S L9 AND NEVR?

L13 2 S L9 AND NERV?


L14 0 S L9 AND EXTRACT?

L15 0 S L9 AND COELOGLOSS?

L16 7 S L3 AND COELOGLOSS?

L17 134 S L3 AND ALZHEIMER?

L18 14 S L17 AND SUCCIN?



chain nodes :
1 2 3 4 5 6 7 8 9 16 23 24 25 26 27 28 29 33 34 38 39 40 41 42

ring nodes :
10 11 12 13 14 15 17 18 19 20 21 22

chain bonds :
1-2 2-3 2-41 3-4 3-7 3-38 4-5 4-39 4-40 5-6 5-42 8-9 11-16 17-26 18-24 19-28 20-29 21-23
22-27 24-25 33-34

ring bonds :
10-11 10-15 11-12 12-13 13-14 14-15 17-18 17-22 18-19 19-20 20-21 21-22

exact/norm bonds :
1-2 2-41 3-7 3-38 4-39 5-6 5-42 10-11 10-15 11-12 11-16 12-13 13-14 14-15 21-23

exact bonds :
2-3 3-4 4-5 4-40 8-9 17-26 18-24 19-28 20-29 22-27 24-25 33-34

normalized bonds :
17-18 17-22 18-19 19-20 20-21 21-22

G1:[*1],[*2],[*3],[*4]

G2:H,[*2],[*3],[*4]

Match level :
1:CLASS2:CLASS3:CLASS4:CLASS5:CLASS6:CLASS7:CLASS8:CLASS9:CLASS10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:CLASS

24:CLASS25:CLASS26:CLASS27:CLASS28:CLASS29:CLASS33:CLASS34:CLASS38:CLASS
39:CLASS40:CLASS41:CLASS42:CLASS

ACCESSION NUMBER: 2005:699596 CAPLUS

DOCUMENT NUMBER: 144:344703

TITLE: Human toxicological effect and damage factors of carcinogenic and noncarcinogenic chemicals for life cycle impact assessment

AUTHOR(S): Huijbregts, Mark A. J.; Rombouts, Linda J. A.; Ragas, Ad M. J.; van de Meent, Dik

CORPORATE SOURCE: Department of Environmental Science, Institute for Wetland and Water Research, Faculty of Science, Radboud University Nijmegen, Nijmegen, 6500GL, Neth.

SOURCE: Integrated Environmental Assessment and Management (2005), 1(3), 181-244

CODEN: IEAMCK; ISSN: 1551-3777

PUBLISHER: Society of Environmental Toxicology and Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Chemical fate, effect, and damage should be accounted for in the anal. of human health impacts by toxic chems. in life cycle assessment (LCA). The goal of this article is to present a new method to derive human damage and effect factors of toxic pollutants, starting from a lognormal dose-response function. Human damage factors are expressed as disability-adjusted life-years (DALYs). Human effect factors contain a disease-specific and a substance-specific component. The disease-specific component depends on the probability of disease occurrence and the distribution of sensitivities in the human population. The substance-specific component, equal to the inverse of the ED50, represents the toxic potency of a substance. The new method has been applied to calculate combined human damage and effect factors for 1192 substances. The total range of 7-9 orders of magnitude between the substances is dominated by the range in toxic potencies. For the combined factors, the typical uncertainty, represented by the square root of the ratio of the 97.5th and 2.5th percentiles, is a factor of 25 for carcinogenic effects and a factor of 125 for noncarcinogenic effects. The interspecies conversion factor, the (non)cancer effect conversion factor, and the average noncancer damage factor dominate the overall uncertainty.


IT 116355-83-0, Fumonisin B1

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (human toxicol. effect and damage factors of carcinogenic and noncarcinogenic chems. for life cycle impact assessment)

RN 116355-83-0 CAPLUS

CN 1,2,3-Propanetricarboxylic acid, 1,1'-[(1S,2R)-1-[(2S,4R,9R,11S,12S)-12-amino-4,9,11-trihydroxy-2-methyltridecyl]-2-[(1R)-1-methylpentyl]-1,2-ethanediyl] ester, (2R,2'R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:


47

THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:101557 CAPLUS
DOCUMENT NUMBER: 144:171021
TITLE: Preparation of piperazine and related N-hydroxy succinic acid diamide derivatives as metalloproteinase inhibitors with therapeutic uses
INVENTOR(S): Swinnen, Dominique; Bombrun, Agnes; Gonzalez, Jerome; Crosignani, Stefano; Gerber, Patrick; Jorand-Lebrun, Catherine
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010751	A1	20060202	WO 2005-EP53616	20050725
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005266313	A1	20060202	AU 2005-266313	20050725
CA 2570903	A1	20060202	CA 2005-2570903	20050725
EP 1771421	A1	20070411	EP 2005-772035	20050725
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
PRIORITY APPLN. INFO.:			EP 2004-103574	A 20040726
			US 2004-591111P	P 20040726
			EP 2005-100641	A 20050131
			US 2005-648924P	P 20050201
			WO 2005-EP53616	W 20050725
OTHER SOURCE(S):	MARPAT 144:171021			
GI				



I



II

AB The present invention is related to piperazine and related N-hydroxy succinic acid diamide derivs. (shown as I; variables defined below; e.g. (2S,3S)-N-hydroxy-2-hydroxy-5-methyl-3-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]hexanamide (shown as II)) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis. A = -C(B)- and N; B is H or B forms a bond with either R5 or R7; R' = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8-cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C3-C8-cycloalkyl C1-C6 alkyl, heterocycloalkyl C1-C6 alkyl, heteroaryl C1-C6 alkyl, amino and alkoxy; R2 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8-cycloalkyl, heterocycloalkyl, alkoxy, aryl and heteroaryl; R3 = H, C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl; R4, R5, R6 and R7 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; or R4 and R7 form together a -CH2-linkage; n is an integer = 1, 2, 3, 4, 5 and 6; Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration = S and R and wherein chiral center (3) has a S configuration as well as pharmaceutically acceptable salts thereof. Methods of preparation are claimed and preps. and/or characterization data for appr. 90 examples of I are included. For example, II was prepared from a 55/45 mixture of (2S)- and (2R)-pentafluorophenyl 2-((4S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)-4-methylpentanoate (preparation by partial diastereoisomerization of latter isomer) by 1st creating an amide linkage using 1-(2-pyridyl)piperazine (40 %) and then a 2nd amide linkage using hydroxylamine (31 %). IC50 values for inhibition of MMP-1, MMP-2, MMP-9 and MMP-12 by 16 examples of I are tabulated. Also, percentage of inhibition of IL-2-induced peritoneal recruitment of lymphocytes (model for cellular migration that occurs during inflammation) by 8 examples of I are tabulated.

IT 85026-06-8P, (2S,3R)-2-Hydroxy-3-methylsuccinic acid
136010-67-8P, (2R,3S)-2-Benzyl-3-hydroxysuccinic acid
152204-30-3P, (2R,3S)-2-Hydroxy-3-methylsuccinic acid
586972-82-9P, (2R,3S)-2-[3-(4-Ethoxyphenyl)propyl]-3-hydroxybutanedioic acid 874646-10-3P 874646-40-9P,
(2R,3S)-2-(Cyclopentylmethyl)-3-hydroxysuccinic acid 874646-78-3P
, (2S,3R)-2-Hydroxy-3-[3-[4-(trifluoromethoxy)phenyl]propyl]butanedioic acid


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperazine and related N-hydroxy succinic acid diamide derivs. as metalloproteinase inhibitors with therapeutic uses)

RN 85026-06-8 CAPLUS

CN Butanedioic acid, 2-hydroxy-3-methyl-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136010-67-8 CAPLUS

CN Butanedioic acid, 2-hydroxy-3-(phenylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 152204-30-3 CAPLUS

CN Butanedioic acid, 2-hydroxy-3-methyl-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 586972-82-9 CAPLUS

CN Butanedioic acid, 2-[3-(4-ethoxyphenyl)propyl]-3-hydroxy-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874646-10-3 CAPLUS

CN L-threo-Pentonic acid, 3-carboxy-3,4-dideoxy-5-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874646-40-9 CAPLUS

CN Butanedioic acid, 2-(cyclopentylmethyl)-3-hydroxy-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 874646-78-3 CAPLUS

CN Butanedioic acid, 2-hydroxy-3-[3-[4-(trifluoromethoxy)phenyl]propyl]-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:370922 CAPLUS

DOCUMENT NUMBER: 140:391301

TITLE: Preparation of benzo-1,3-diazepin-2-ones and related compounds as CGRP receptor antagonists for the treatment of migraine headaches

INVENTOR(S): Rudolf, Klaus; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Dreyer, Alexander; Bauer, Eckhart; Schindler, Marcus; Kirsten, Arndt; Doods, Henri

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 315 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037810	A1	20040506	WO 2003-EP11762	20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10250080	A1	20040513	DE 2002-10250080	20021025
US 2006079504	A1	20060413	US 2003-687262	20031016
CA 2503455	A1	20040506	CA 2003-2503455	20031023
AU 2003276156	A1	20040513	AU 2003-276156	20031023
EP 1558600	A1	20050803	EP 2003-809317	20031023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015665	A	20050830	BR 2003-15665	20031023
CN 1708493	A	20051214	CN 2003-80102004	20031023
JP 2006516244	T	20060629	JP 2004-545963	20031023
IN 2005DN01640	A	20070323	IN 2005-DN1640	20050421
NO 2005002496	A	20050624	NO 2005-2496	20050524
PRIORITY APPLN. INFO.:			DE 2002-10250080	A 20021025
			US 2002-426168P	P 20021114
			WO 2003-EP11762	W 20031023

OTHER SOURCE(S): MARPAT 140:391301
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = O, S, phenylsulfonylimino, etc.; X = O, S, substituted imino, etc.; U = alkyl, alkenyl, alkynyl, etc.; V = Cl, Br, amino, etc.; W = H, halo, difluoromethyl, etc.; R1 = 5-7 membered aza, diaza, triaza, etc. heterocycle; R2 = H, phenylmethyl, alkyl, etc.; R3 = H, Ph, pyridinyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared. For example, benzo-1,3-diazepin-2-one II was prepared from 4-amino-3-chloro-5-trifluoromethylbenzoic acid in 9-steps. In human CGRP receptor binding affinity assays, compds. I exhibited IC50 values < 10000 nM. Compds. I are claimed useful for the treatment of migraine headaches.

IT 688020-83-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP receptor antagonists for the treatment of migraine headaches)

RN 688020-83-9 CAPLUS

CN Butanedioic acid, [[4-amino-3-chloro-5-(trifluoromethyl)phenyl]methyl]-, 1-methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 688020-73-7P 688020-93-1P 688021-41-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of benzo-1,3-diazepin-2-ones and related compds. as CGRP

receptor antagonists for the treatment of migraine headaches)

RN 688020-73-7 CAPLUS

CN Butanedioic acid, [[4-amino-3-bromo-5-(trifluoromethyl)phenyl]methyl]-, 1-methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688020-93-1 CAPLUS


CN Butanedioic acid, [[4-amino-3,5-bis(trifluoromethyl)phenyl]methyl]-, 1-methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 688021-41-2 CAPLUS

CN Butanedioic acid, [[4-chloro-3-(trifluoromethyl)phenyl]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1133707 CAPLUS

DOCUMENT NUMBER: 146:75146

TITLE: Dactylorhin B reduces toxic effects of β -amyloid fragment (25-35) on neuron cells and isolated rat brain mitochondria

AUTHOR(S): Zhang, Dan; Zhang, Yi; Liu, Gengtao; Zhang, Jianjun

CORPORATE SOURCE: Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (2006), 374(2), 117-125

CODEN: NSAPCC; ISSN: 0028-1298

PUBLISHER: Springer

DOCUMENT TYPE: Journal

LANGUAGE: English

AB β -Amyloid is strongly implicated in Alzheimer's pathol., and mitochondria play an important role in neurodegenerative disorders. Dactylorhin B [short for bis(4- β -D-glucopyranosyloxybenzyl)-2- β -D-glucopyranosyl-2-isobutyltartrate (DHB)] is an active compound isolated from *Coeloglossum viride*. (L.) Hartm. var. *bracteatum* (Willd.) and may have neuroprotective effects. In the present study, the authors investigated the damage of rat brain mitochondrial function induced by β -amyloid and the protective effect of DHB. Isolated rat brain mitochondria were incubated with amyloid- β peptide (A β)25-35 alone or together with DHB. Reactive oxygen species production, pyruvate dehydrogenase complex activity, α -ketoglutarate dehydrogenase complex activity, cytochrome c oxidase activity, mitochondrial swelling, mitochondrial membrane potential and the release of cytochrome c from mitochondria were measured. Data showed that A β 25-35 directly disrupted mitochondrial function, inhibited the key enzymes and contributed to apoptosis and the deficiency of energy metabolism. Coincubation of DHB attenuated A β 25-35-induced pathol. changes. The significance of DHB in the management of mitochondria-related disorders is discussed.

IT 256459-36-6, Dactylorhin B



RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dactylorhin B reduces toxic effects of β -amyloid fragment (25-35) on neuron cells and isolated rat brain mitochondria)

RN 256459-36-6 CAPLUS

CN β -D-Glucopyranoside, [(2R,3S)-2-(β -D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:153333 CAPLUS

DOCUMENT NUMBER: 144:304975

TITLE: Effects of *Coeloglossum. viride* var. bracteatum extract on memory deficits and pathological changes in senescent mice

AUTHOR(S): Zhang, Dan; Liu, Geng-tao; Shi, Jian-gong; Zhang, Jian-jun

CORPORATE SOURCE: Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Peop. Rep. China

SOURCE: Basic & Clinical Pharmacology & Toxicology (2006),

98(1), 55-60

CODEN: BCPTBO; ISSN: 1742-7835

PUBLISHER:

Blackwell Publishing Ltd.

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB Previous studies have shown that injection of D-galactose could result in senescent performances in animals, that injection of NaNO_2 could cause ischemia and hypoxia in many organs, and combined injection of D-galactose and NaNO_2 make normal mice taking on senescent performances in a shorter period. The aim of this study was to investigate the effects of CE, an extract from a Tibetan medicinal herb, *Coeloglossum. viride* (L.) Hartm. var. *bracteatum* (Willd.), on senescent mice. The step-down test was performed to evaluate the learning and memory function of mice. The activities of superoxide dismutase, ATPase, monoamine oxydase and the content of malondialdehyde were measured to determine the impairment of brain. The expressions of Bcl-2, Bax, and caspase-3 proteins in mouse hippocampus were studied by immunohistochem. staining. The data demonstrated that D-galactose and NaNO_2 treated mice had significant deficits in learning and memory function. The reduced activities of superoxide dismutase, ATPase, increased activities of monoamine oxydase and level of malondialdehyde were also found. Bax and caspase-3 pos. cells increased while Bcl-2 pos. cells decreased remarkably. Treatment of CE (2.5, 5 mg · kg⁻¹) ameliorated the memory impairment; rectified the biochem. and neural system changes in mice. These results suggest that CE offers promise as a tool for treatment of senescence-related diseases.

IT 256459-34-4P, Dactylorhin A 256459-36-6P, Dactylorhin B

RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(effects of *Coeloglossum. viride* var. *bracteatum* extract on memory deficits and pathol. changes in senescent mice)


RN 256459-34-4 CAPLUS

CN β -D-Glucopyranoside, [(2R)-2-(β -D-glucopyranosyloxy)-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


PAGE 1-A






RN 256459-36-6 CAPLUS
 CN β -D-Glucopyranoside, [(2R,3S)-2-(β -D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxymethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:565079 CAPLUS

DOCUMENT NUMBER: 141:117176

TITLE: The use of succinate derivative esters for the treatment of dementia

INVENTOR(S): Zhang, Jianjun; Shi, Jiangong; Wang, Yafang; Zhang, Dan; Gao, Mei; Yang, Yongchun; Huang, Shengyang

PATENT ASSIGNEE(S): Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058244	A1	20040715	WO 2003-CN1155	20031231
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CN 1511520	A	20040714	CN 2002-159342	20021231
CA 2512187	A1	20040715	CA 2003-2512187	20031231
AU 2003292876	A1	20040722	AU 2003-292876	20031231
EP 1582209	A1	20051005	EP 2003-782083	20031231
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017217	A	20051101	BR 2003-17217	20031231
CN 1731991	A	20060208	CN 2003-80107864	20031231

JP 2006512373	T	20060413	JP 2004-562475	20031231
US 2006281692	A1	20061214	US 2005-541082	20050629
PRIORITY APPLN. INFO.:			CN 2002-159342	A 20021231
			WO 2003-CN1155	W 20031231

OTHER SOURCE(S): MARPAT 141:117176

AB The use of extract from Wangla (*coeloglossum viride* (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutically acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can

improve

learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by β -amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.

IT 150975-91-0P 721885-36-5P 721885-37-6P
721885-38-7P 721885-39-8P 721885-40-1P
721885-41-2P 721885-42-3P 721885-43-4P
721885-44-5P 721885-45-6P 721885-46-7P
721885-48-9P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(succinate derivative esters from Wangla (*coeloglossum viride*) for treatment of dementia)

RN 150975-91-0 CAPLUS


CN β -D-Glucopyranoside, [2-hydroxy-2-(1-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxymethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 721885-36-5 CAPLUS

CN β -D-Glucopyranoside, 4-[[[2-(carboxyhydroxymethyl)-2-hydroxy-4-methyl-

1-oxopentyl]oxy)methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-37-6 CAPLUS

CN β -D-Glucopyranoside, 4-[[3-carboxy-2,3-dihydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-38-7 CAPLUS

CN β -D-Glucopyranoside, 4-[[[2-(carboxyhydroxymethyl)-2-(β -D-glucopyranosyloxy)-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-39-8 CAPLUS

CN β -D-Glucopyranoside, 4-[[[3-carboxy-3-(β -D-glucopyranosyloxy)-2-hydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-40-1 CAPLUS

CN Butanedioic acid, 2-(β-D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 721885-41-2 CAPLUS

CN β-D-Glucopyranoside, [2-(β-D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxymethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 721885-42-3 CAPLUS


CN β -D-Glucopyranoside, [2,3-dihydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 721885-43-4 CAPLUS


CN β -D-Glucopyranoside, [2-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 721885-44-5 CAPLUS

CN β -D-Glucopyranoside, 4-[[2-hydroxy-4-methoxy-2-(1-methylethyl)-1,4-dioxobutoxy]methyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 721885-45-6 CAPLUS

CN β -D-Glucopyranoside, [2-(β -D-glucopyranosyloxy)-2-(1-methylethyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A







RN 721885-46-7 CAPLUS
 CN β -D-Glucopyranoside, 4-[[[2-(carboxymethyl)-2-(β -D-glucopyranosyloxy)-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 721885-48-9 CAPLUS
 CN β -D-Glucopyranoside, [2-(β -D-glucopyranosyloxy)-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:907258 CAPLUS

DOCUMENT NUMBER: 141:170855

TITLE: Chemical constituents of the rhizomes of *Coeloglossum viride* var. *bracteatum*

AUTHOR(S): Huang, Sheng-Yang; Li, Guo-Qiang; Shi, Jian-Gong; Mo, Shun-Yan; Wang, Su-Juan; Yang, Yong-Chun

CORPORATE SOURCE: Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China

SOURCE: Journal of Asian Natural Products Research (2004), 6(1), 49-61

CODEN: JANRFI; ISSN: 1028-6020

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal
LANGUAGE: English

AB Seven new compds., named coelovirins A-G (1-7), along with fourteen known constituents were isolated from the rhizomes of *Coeloglossom viride* var. *bracteatum* (Orchidaceae). On the basis of chemical and spectroscopic methods, including 2D-NMR techniques, the structures of new compds. were elucidated as 1-(4- β -D-glucopyranosyloxybenzyl)-(2R,3S)-2-isobutyltartrate (1), 4-(4- β -D-glucopyranosyloxybenzyl)-(2R,3S)-2-isobutyltartrate (2), 1-(4- β -D-glucopyranosyloxybenzyl)-(2R,3S)-2- β -D-glucopyranosyl-2-isobutyltartrate (3), 4-(4- β -D-glucopyranosyloxybenzyl)-(2R,3S)-2- β -D-glucopyranosyl-2-isobutyltartrate (4), (2R,3S)-2- β -D-glucopyranosyl-2-isobutyltartaric acid (5), bis(4- β -D-glucopyranosyloxybenzyl)-(2R,3S)-2-[β -D-glucopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl]-2-isobutyltartrate (6) and bis(4- β -D-glucopyranosyloxybenzyl)-(2R)-2-[β -D-glucopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl]-2-isobutylmalate (7). The known compds. are 4-hydroxybenzaldehyde, 4-hydroxybenzyl alc., 4,4'-dihydroxydibenzyl ether, 4,4'-dihydroxydiphenylmethane, 4-(4-hydroxybenzyloxy)benzyl alc., gastrodin, quercetin-3,7-diglucoside, thymidine, loroglossin, militarine, dactylorhin A, dactylorhin B, β -sitosterol and daucosterol.


IT 256459-39-9P, Coelovirin C 452963-01-8P, Coelovirin A
452963-02-9P, Coelovirin B 640749-82-2P, Coelovirin D
732304-96-0P, Coelovirin E 732305-41-8P, Coelovirin F
732305-55-4P, Coelovirin G

RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation) (chemical constituents of the rhizomes of *Coeloglossum viride* var. *bracteatum*)

RN 256459-39-9 CAPLUS

CN β -D-Glucopyranoside, 4-[[[(2R)-2-[(S)-carboxyhydroxymethyl]-2-(β -D-glucopyranosyloxy)-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 452963-01-8 CAPLUS

CN β -D-Glucopyranoside, 4-[[[(2R)-2-[(S)-carboxyhydroxymethyl]-2-hydroxy-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 452963-02-9 CAPLUS

CN β -D-Glucopyranoside, 4-[[[(2S,3R)-3-carboxy-2,3-dihydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 640749-82-2 CAPLUS

CN β -D-Glucopyranoside, 4-[[[(2S,3R)-3-carboxy-3-(β -D-glucopyranosyloxy)-2-hydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 732304-96-0 CAPLUS

CN Butanedioic acid, 2-(β -D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 732305-41-8 CAPLUS
 CN β -D-Glucopyranoside, [(2R,3S)-2-[(4-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-3-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation. (-).

PAGE 1-A




OH

RN 732305-55-4 CAPLUS

CN β -D-Glucopyranoside, [(2R)-2-[(4-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





IT 256459-34-4P, Dactylorhin A 256459-36-6P, Dactylorhin B
 RL: BSU (Biological study, unclassified); PUR (Purification or recovery);
 BIOL (Biological study); PREP (Preparation)
 (chemical constituents of the rhizomes of *Coeloglossum viride*
 var. *bracteatum*)

RN 256459-34-4 CAPLUS

CN β -D-Glucopyranoside, [(2R)-2-(β -D-glucopyranosyloxy)-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 256459-36-6 CAPLUS

CN β -D-Glucopyranoside, [(2R,3S)-2-(β -D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxymethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:697554 CAPLUS

DOCUMENT NUMBER: 140:73984

TITLE: Two new tartrate derivative glucosides from
Coeloglossum viride (L.) Hartm. var.
bracteatum (Willd.) Richter

AUTHOR(S): Huang, Sheng Yang; Shi, Jian Gong; Yang, Yong Chun;
Tu, Peng Fei

CORPORATE SOURCE: Department of Natural Medicines, School of
Pharmaceutical Sciences, Peking University, Beijing,
100083, Peop. Rep. China

SOURCE: Chinese Chemical Letters (2003), 14(8), 814-817

PUBLISHER:	CODEN: CCLEE7; ISSN: 1001-8417
DOCUMENT TYPE:	Chinese Chemical Society
LANGUAGE:	Journal
GI	English

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Two new tartrate derivative glucosides, coelovirin C (I) and D (II), were isolated from rhizomes of *Coeloglossum viride* (L.) Hartm. var. *bracteatum* (Willd.) Richter (Orchidaceae). Their structures were elucidated as (2R, 3S)-2-β-D-glucopyranosyl-2-isobutyltartrate-1-(4-β-D-glucopyranosyloxybenzyl) ester I and (2R,3S)-2-β-D-glucopyranosyl-2-isobutyltartrate-4-(4-β-D-glucopyranosyloxybenzyl) ester II by means of chemical and spectroscopic methods.

IT 256459-39-9P, Coelovirin C 640749-82-2P, Coelovirin D
 RL: NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
 (tartrate derivative glucosides from *Coeloglossum viride* var. *bracteatum*)

RN 256459-39-9 CAPLUS

CN β-D-Glucopyranoside, 4-[[[(2R)-2-[(S)-carboxyhydroxymethyl]-2-(β-D-glucopyranosyloxy)-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 640749-82-2 CAPLUS

CN β-D-Glucopyranoside, 4-[[[(2S,3R)-3-carboxy-3-(β-D-glucopyranosyloxy)-2-hydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:505946 CAPLUS
 DOCUMENT NUMBER: 137:198319
 TITLE: Two new isobutyltartrate monoesters from
 Coeloglossum viride (L.) Hartm. var.
 bracteatum (Willd.) Richter
 AUTHOR(S): Huang, Sheng Yang; Shi, Jian Gong; Yang, Yong Chun;
 Hu, Shi Lin
 CORPORATE SOURCE: Institute of Chinese Materia Medica, Chinese Academy
 of Traditional Chinese Medicine, Beijing, 100700,
 Peop. Rep. China
 SOURCE: Chinese Chemical Letters (2002), 13(6), 551-554
 CODEN: CCLEE7; ISSN: 1001-8417
 PUBLISHER: Chinese Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Two new isobutyltartrate monoesters, coclovirin A (I) and B (II), were isolated from the rhizomes of Coeloglossum viride (L.) Hartm. var. bracteatum (Willd.) Richter (Orchidaceae). Their structures were elucidated as (2R, 3S)-2-isobutyltartrate-1-(4-β-D-glucopyranosyloxybenzyl) ester I and (2R, 3S)-2-isobutyltartrate-4-(4-β-D-glucopyranosyloxybenzyl) ester II on the basis of phys. consts. and spectroscopic methods including 2D NMR techniques.
 IT 452963-01-8P, Coelovirin A 452963-02-9P, Coelovirin B
 RL: NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
 (isobutyltartrate monoesters from Coeloglossum viride var. bracteatum)
 RN 452963-01-8 CAPLUS
 CN β-D-Glucopyranoside, 4-[[[(2R)-2-[(S)-carboxyhydroxymethyl]-2-hydroxy-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 452963-02-9 CAPLUS

CN β -D-Glucopyranoside, 4-[[[(2S,3R)-3-carboxy-2,3-dihydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:382606 CAPLUS

DOCUMENT NUMBER: 137:213593

TITLE: Studies on the chemical constituents of
Coeloglossum viride Hartm. var. bracteatum
(Willd.) Richter

AUTHOR(S): Huang, Shengyang; Shi, Jiangong; Yang, Yongchun; Hu, Shilin

CORPORATE SOURCE: Institute of Materia Medica, Chinese Academy of
Medical Sciences and Peking Union Medical College,
Beijing, 100050, Peop. Rep. China


SOURCE: Yaoxue Xuebao (2002), 37(3), 199-203
CODEN: YHHPAL; ISSN: 0513-4870

PUBLISHER: Yaoxue Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI



AB The chemical constituents of the rhizomes of *Coeloglossum viride* (L.) Hartm. var. *bracteatum* (Willd.) Richter were studied. The compds. were isolated with normal phase and reverse phase column chromatog. methods and HPLC. Their structures were elucidated based on phys. consts. and spectral anal. (UV, IR, EI-MS, pos. and neg. FAB-MS, APCI-MS, ¹HNMR, ¹³CNMR, DEPT, ¹H-¹H COSY, HMQC, and HMBC). Eight compds. were obtained from the ethanolic extract of the rhizomes of this plant: dactylorhin B, loroglossin, dactylorhin A, militarine, coelovirin A (I), gastrodin, thymidine, and quercetin-3,7-di-O- β -D-glucopyranoside. All the compds. were obtained from this plant and genus *Coeloglossum* for the first time. Compound I was a new one.


IT 256459-34-4, Dactylorhin A 256459-36-6, Dactylorhin B
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (constituents from *Coeloglossum viride* var. *bracteatum*)


RN 256459-34-4 CAPLUS

CN β -D-Glucopyranoside, [(2R)-2-(β -D-glucopyranosyloxy)-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxymethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


PAGE 1-A






RN 256459-36-6 CAPLUS
 CN β -D-Glucopyranoside, [(2R,3S)-2-(β -D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxymethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).





IT 452963-01-8P, Coelovirin A
 RL: NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
 (constituents from *Coeloglossum viride* var. *bracteatum*)
 RN 452963-01-8 CAPLUS
 CN β -D-Glucopyranoside, 4-[[[(2R)-2-[(S)-carboxyhydroxymethyl]-2-hydroxy-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



ACCESSION NUMBER: 2004:565079 CAPLUS
 DOCUMENT NUMBER: 141:117176
 TITLE: The use of succinate derivative esters for the treatment of dementia
 INVENTOR(S): Zhang, Jianjun; Shi, Jiangong; Wang, Yafang; Zhang, Dan; Gao, Mei; Yang, Yongchun; Huang, Shengyang
 PATENT ASSIGNEE(S): Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058244	A1	20040715	WO 2003-CN1155	20031231
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CN 1511520	A	20040714	CN 2002-159342	20021231
CA 2512187	A1	20040715	CA 2003-2512187	20031231
AU 2003292876	A1	20040722	AU 2003-292876	20031231
EP 1582209	A1	20051005	EP 2003-782083	20031231
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003017217	A	20051101	BR 2003-17217	20031231
CN 1731991	A	20060208	CN 2003-80107864	20031231
JP 2006512373	T	20060413	JP 2004-562475	20031231
US 2006281692	A1	20061214	US 2005-541082	20050629
PRIORITY APPLN. INFO.:			CN 2002-159342	A 20021231
			WO 2003-CN1155	W 20031231

OTHER SOURCE(S): MARPAT 141:117176

AB The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutically acceptable salts thereof, for the manufacture of a

pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment, it has been demonstrated that, succinate derivative esters can improve learning and memory ability in dementia rats induced by scopolamine and cyclohexenyl imine; improve learning and memory ability in dementia rats induced by β -amyloid; improve learning and memory ability in dementia rats induced by permanent ligation of bilateral carotid; and improve memory ability of normal animals. It has the advantage of high activity, low toxicity and no inhibition to cholinesterase.

IT 150975-91-0P 721885-36-5P 721885-37-6P
 721885-38-7P 721885-39-8P 721885-40-1P
 721885-41-2P 721885-42-3P 721885-43-4P
 721885-44-5P 721885-45-6P 721885-46-7P
 721885-48-9P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)


(succinate derivative esters from Wangla (coeloglossum viride)
for treatment of dementia)

RN 150975-91-0 CAPLUS


CN β -D-Glucopyranoside, [2-hydroxy-2-(1-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 721885-36-5 CAPLUS

CN β -D-Glucopyranoside, 4-[[[2-(carboxyhydroxymethyl)-2-hydroxy-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-37-6 CAPLUS

CN β -D-Glucopyranoside, 4-[[[3-carboxy-2,3-dihydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-38-7 CAPLUS

CN β-D-Glucopyranoside, 4-[[[2-(carboxyhydroxymethyl)-2-(β-D-glucopyranosyloxy)-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-39-8 CAPLUS

CN β-D-Glucopyranoside, 4-[[[3-carboxy-3-(β-D-glucopyranosyloxy)-2-hydroxy-5-methyl-1-oxohexyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-40-1 CAPLUS

CN Butanedioic acid, 2-(β-D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 721885-41-2 CAPLUS

CN β -D-Glucopyranoside, [2-(β -D-glucopyranosyloxy)-3-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 721885-42-3 CAPLUS
 CN β -D-Glucopyranoside, [2,3-dihydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 721885-43-4 CAPLUS
 CN β -D-Glucopyranoside, [2-hydroxy-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 721885-44-5 CAPLUS

CN β -D-Glucopyranoside, 4-[[2-hydroxy-4-methoxy-2-(1-methylethyl)-1,4-dioxobutoxy]methyl]phenyl (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 721885-45-6 CAPLUS

CN β -D-Glucopyranoside, [2-(β -D-glucopyranosyloxy)-2-(1-methylethyl)-1,4-dioxo-1,4-butanediyl]bis(oxyethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 721885-46-7 CAPLUS

CN β -D-Glucopyranoside, 4-[[[2-(carboxymethyl)-2-(β -D-glucopyranosyloxy)-4-methyl-1-oxopentyl]oxy]methyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 721885-48-9 CAPLUS

CN β -D-Glucopyranoside, [2-(β -D-glucopyranosyloxy)-2-(2-methylpropyl)-1,4-dioxo-1,4-butanediyl]bis(oxymethylene-4,1-phenylene) bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT